ReviewMediators of inflammation2012
Macrolide therapy in chronic inflammatory diseases.
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis.Scientific reports · 2021Pooled it
- Role of Serum Inflammatory Biomarkers in Risk Stratification of Hospitalized Children with Macrolide-Non-ResponsiveChildren (Basel, Switzerland) · 2026Article
- Investigation of the Binding of the Macrolide Antibiotic Telithromycin to Human Serum Albumin by NMR Spectroscopy.International journal of molecular sciences · 2025Article
- Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.EXCLI journal · 2024Review
- An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis.Journal of personalized medicine · 2023Review
- Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules.PloS one · 2023Article
- Drug repositioning prediction for psoriasis using the adverse event reporting database.Frontiers in medicine · 2023Article
- Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD.Journal of general internal medicine · 2022Article
- Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.ACS pharmacology & translational science · 2022Article
- Antibiotic Resistance in Bacteria-A Review.Antibiotics (Basel, Switzerland) · 2022Review
- Case report: Idiopathic subglottic stenosis in a girl; successful treatment with macrolides.Frontiers in pediatrics · 2022Article
- The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.Frontiers in immunology · 2022Review
- Determination of Lekethromycin, a Novel Macrolide Lactone, in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study.Molecules (Basel, Switzerland) · 2020Article
- Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients.Saudi medical journal · 2020Article
- Covid-19 and drug therapy, what we learned.International journal of clinical pharmacy · 2020Review
- SIME: synthetic insight-based macrolide enumerator to generate the V1B library of 1 billion macrolides.Journal of cheminformatics · 2020Article
- Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity.Biochemical pharmacology · 2019Article
- Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Pathogenesis and Treatment of Neurologic Diseases Associated WithFrontiers in microbiology · 2018Review
- Learning Microbial Community Structures with Supervised and Unsupervised Non-negative Matrix Factorization.Microbiome · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrolides are a group of antibiotics with a distinctive macrocyclic lactone ring combined with sugars (cladinose, desosamine). The action of macrolides is to block protein synthesis by binding to the subunit of 50S ribosome of bacteria. Prototype macrolide was erythromycin, which came into clinical practice in the 50s of the 20th century. Its antimicrobial spectrum covers the scope of the penicillins but is extended to the impact of atypical bacteria. In the 90 s more drugs of this group were synthesized-they have less severe side effects than erythromycin, extended spectrum of Gram-negative bacteria. Macrolides are effective in treating mycobacterial infections especially in patients infected with HIV. It is now known that in addition to antibacterial abilities, macrolides have immunomodulatory effects-they inhibit the production of proinflammatory cytokines (TNF, IL1, 6, and 8) affect transcription factors (NF-κB) as well as costimulaton (CD 80) and adhesion molecules (ICAM). This review article focused not only on the their antimicrobial abilities but also on efficacy in the treatment of several inflammatory disorders independent of the infectious agent. Their wider use as immunomodulators requires further study, which can lead to an extension of indications for their administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.